Literature DB >> 19563542

Extralysosomal protein degradation in myofibrillar myopathies.

Montse Olivé1.   

Abstract

Myofibrillar myopathies (MFMs) are a group of heterogeneous muscle disorders morphologically defined by the presence of foci of dissolution of the myofibrils, accumulation of the products of myofibrillar degradation and ectopic expression of multiple proteins. MFMs represent the paradigm of conformational protein diseases of skeletal and cardiac muscles. Protein aggregation in MFMs is now considered to be the result of a failure of the extralysosomal proteolytic degradation system. Several factors including mutant proteins, aggresome formation and oxidative stress may compromise the ubiquitin-proteasome system, promoting the accumulation of potentially toxic protein aggregates within muscle cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563542     DOI: 10.1111/j.1750-3639.2009.00288.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  6 in total

1.  MYH7 mutation associated with two phenotypes of myopathy.

Authors:  Nan Li; Zhe Zhao; Hongrui Shen; Qi Bing; Xuan Guo; Jing Hu
Journal:  Neurol Sci       Date:  2017-11-24       Impact factor: 3.307

2.  A combined laser microdissection and mass spectrometry approach reveals new disease relevant proteins accumulating in aggregates of filaminopathy patients.

Authors:  Rudolf A Kley; Alexandra Maerkens; Yvonne Leber; Verena Theis; Anja Schreiner; Peter F M van der Ven; Julian Uszkoreit; Christian Stephan; Stefan Eulitz; Nicole Euler; Janbernd Kirschner; Klaus Müller; Helmut E Meyer; Martin Tegenthoff; Dieter O Fürst; Matthias Vorgerd; Thorsten Müller; Katrin Marcus
Journal:  Mol Cell Proteomics       Date:  2012-10-31       Impact factor: 5.911

3.  Chemical chaperone ameliorates pathological protein aggregation in plectin-deficient muscle.

Authors:  Lilli Winter; Ilona Staszewska; Eva Mihailovska; Irmgard Fischer; Wolfgang H Goldmann; Rolf Schröder; Gerhard Wiche
Journal:  J Clin Invest       Date:  2014-03       Impact factor: 14.808

4.  Clinical, morphological and genetic studies in a cohort of 21 patients with myofibrillar myopathy.

Authors:  G Vattemi; M Neri; S Piffer; P Vicart; F Gualandi; M Marini; V Guglielmi; M Filosto; P Tonin; A Ferlini; G Tomelleri
Journal:  Acta Myol       Date:  2011-10

5.  Differential proteomic analysis of abnormal intramyoplasmic aggregates in desminopathy.

Authors:  A Maerkens; R A Kley; M Olivé; V Theis; P F M van der Ven; J Reimann; H Milting; A Schreiner; J Uszkoreit; M Eisenacher; K Barkovits; A K Güttsches; J Tonillo; K Kuhlmann; H E Meyer; R Schröder; M Tegenthoff; D O Fürst; T Müller; L G Goldfarb; M Vorgerd; K Marcus
Journal:  J Proteomics       Date:  2013-04-30       Impact factor: 4.044

6.  New insights into the protein aggregation pathology in myotilinopathy by combined proteomic and immunolocalization analyses.

Authors:  A Maerkens; M Olivé; A Schreiner; S Feldkirchner; J Schessl; J Uszkoreit; K Barkovits; A K Güttsches; V Theis; M Eisenacher; M Tegenthoff; L G Goldfarb; R Schröder; B Schoser; P F M van der Ven; D O Fürst; M Vorgerd; K Marcus; R A Kley
Journal:  Acta Neuropathol Commun       Date:  2016-02-03       Impact factor: 7.801

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.